Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
ACHFF
Primary Symbol:
V.ARCH
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok...
). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 18, 2024 7:28am
New Press Release - Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virus Phase II findings previously disclosed support dipeptidase-1 (DPEP...
read article.
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Mar 15, 2024 4:37pm
More great News today
with 1 Canadian site in Calgary and two more coming plus additional 3 sites in Turkey which will bring us to 9. It will be a big bonus if we get a few USA sites get us to 12-15 total sites. Momentum
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 15, 2024 7:05am
New Press Release - University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgary’s Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the...
read article.
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Mar 07, 2024 8:33am
Awesome News
First dosing commenced and 3 sites confirmed with additional 3 sites coming. Off to the races! Now we wait for Canadian sites and dosing to commence there. We now have two different drugs for AKI
...more
(1931)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Mar 07, 2024 8:19am
Arch Biopartners Dosing of First Patient in Phase II Trial
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 07, 2024 7:26am
New Press Release - Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...
read article.
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Mar 06, 2024 9:46am
Turkish Trial
Well we missed the February deadline for first dosing and not one word or update from management. This trial was initially scheduled to commence in the fall of 2023 with first dosing, then moved to
...more
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Comment by
Viking2233
on Feb 28, 2024 12:02pm
RE:RE:1 day to go
I agree with your post. I am suggesting it is fluff being the meeting was PRE IND and premature in regards to commencement date. My point is they have failed to hit previous target dates with current
...more
(5)
•••
TheBearInTheWoods
X
View Profile
View Bullboard History
Comment by
TheBearInTheWoods
on Feb 28, 2024 11:12am
RE:1 day to go
I imagine you are new to the sector to say that announcing a Pre-IND is fluff news. The company is moving forward after interest with clinical teams on TWO more human trials .... The drug is being
...more
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Feb 28, 2024 10:44am
1 day to go
Well yesterdays bump was short lived. February 28th today and again no news. Only 1 day left in February to announce 1st dosing and if I was a betting man it doesn't happen. Something not
...more
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Feb 27, 2024 4:30pm
Nice Surprise News Release
The news release today was a welcome surprise and took out Scotiabank wall at $1.60 and we marched up to $1.69 and back down to $1.60. I believe all eyes will be watching to see if we announce our
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Feb 27, 2024 10:32am
Arch Biopartners Cilistatin Breakthrough Article
Arch Biopartners Cilistatin Breakthrough
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Feb 27, 2024 10:30am
Arch has Pre-IND Meeting with FDA - Cilistatin
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury 2024-02-27 07:25:25 AM ET (GlobeNewswire) TORONTO, Feb. 27
...more
(301)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Feb 26, 2024 8:05am
Management Credibility
is on the line this week. My fingers are crossed that we announce first dosing on or before Feb 29, 2024. If first dosing is not announced it will be a major setback for management. I truly am
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Drilling Approval Received for New Mexico Lithium Project
GameSquare Announces Formation of FaZe Media, Backed by $11M Investment
Xcyte Digital Corp. Releases "Xperience" Subscription Service